Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

OCU410ST

Gene therapy (AAV vector) · Gene replacement · developed by Ocugen

Phase 2/3 Most advanced trial

OCGN Developer

1 Registered trials

What is OCU410ST?

OCU410ST is an AAV-based gene therapy administered subretinally for Stargardt disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene therapy (AAV vector)
Mechanism: Gene replacement
Therapy area: Ophthalmology
Developer: Ocugen (OCGN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05956626	Phase 2/3	Stargardt Disease	Active not recruiting	OCGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Stargardt Disease

More from Ocugen

OCU200 Phase 1 OCU400 Phase 1/2 OCU410 Phase 3

Sources

ClinicalTrials.gov NCT05956626

Updated Oct 3, 2026. Something wrong or missing? Report it on the OCGN page.

Follow OCGN, the company behind OCU410ST

See OCGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCGN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z